Cancer Genetics, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
Published on: Monday, February 13th, 2017 View all Media
RUTHERFORD, NJ / GLOBE NEWSWIRE / February 13, 2017 / Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will be presenting at the 2nd annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 11:15 AM EST. Panna Sharma, CEO and President of Cancer Genetics, will be presenting, as well as meeting with investors.
The 2017 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
A webcast of the presentation will be available at http://www.investorcalendar.com/event/11203
ABOUT CANCER GENETICS
Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, Australia and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.